2021-01-05 13:12:00+00:00
 They include more than 300 price increases from companies like Pfizer and GlaxoSmithKline reported by Reuters late last week.
Abbvie raised prices on around 40 drugs including a 7.4% hike on rheumatoid arthritis treatment Humira, the world’s top-selling drug.
Bristol Myers hiked prices on around a dozen drugs, including cancer drugs Revlimid and Opdivo by 4.5 percent and 1.5 percent, respectively.
Drug price increases have slowed substantially since 2015, both in terms of the size of the hikes and the number of drugs affected.
“With price increases losing their impact, launch prices will be the primary driver of U.S. drug list price inflation.”